Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

What happened: Vaxcyte (Nasdaq: PCVX) said it will host a webcast and conference call on October 5, 2026 to present topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. Key numbers: Call at 8:00 a.m. ET / 5:00 a.m. PT on October 5, 2026. Conference ID PCVX1005. Webcast archived at least 30 days. VAX-31 is 31-valent; VAX-24 is 24-valent. Why it matters: The call will present OPUS-1 topline data on safety, tolerability and immunogenicity. Vaxcyte describes VAX-31 as the broadest-spectrum PCV candidate in the clinic today.

Vaxcyte (Nasdaq: PCVX) said it will host a webcast and conference call on October 5, 2026 to present topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate.

The call will present OPUS-1 topline data on safety, tolerability and immunogenicity. Vaxcyte describes VAX-31 as the broadest-spectrum PCV candidate in the clinic today.